Table 3. Univariate and multi-variate analysis of the clinicopathological and molecular features for OS in LUAD.
Clinicopathological parameters | Comparison reference | Univariate analysis | Multi-variate analysis | ||
---|---|---|---|---|---|
Hazard ratio (95%CI) | P value | Hazard ratio (95%CI) | P value | ||
Age | < 65 | Ref | Ref | ||
≥ 65 | 1.906 (1.079–3.366) | 0.026 | 1.566 (0.838–2.926)a | 0.159a | |
Gender | Male | Ref | |||
Female | 1.176 (0.640–2.160) | 0.602 | |||
Smoke | No | Ref | |||
Yes | 1.577 (0.891–2.790) | 0.118 | |||
Clinical Stage | IA | Ref | < 0.001 | Ref | < 0.001a |
IB | 1.058 (0.177–6.338) | 0.951 | 0.907 (0.150–5.499)a | 0.916a | |
IIA | 4.515 (0.934–21.817) | 0.061 | 4.513 (0.919–22.164)a | 0.064a | |
IIB | 6.102 (1.397–26.660) | 0.016 | 4.278 (0.966–18.945)a | 0.056a | |
IIIA | 19.666 (4.234–91.348) | < 0.001 | 13.101 (2.796–61.386)a | 0.001a | |
IIIB | 10.963 (2.415–49.760) | 0.002 | 6.050 (1.307–27.996)a | 0.021a | |
Target therapy | Yes | Ref | Ref | ||
No | 2.000 (1.129–3.542) | 0.018 | 1.697 (0.934–3.083)a | 0.083a | |
IL-1β level | Low | Ref | Ref | ||
High | 3.818 (1.986–7.339) | < 0.001 | 3.166 (1.592–6.297)a | 0.001a | |
TNF-α level | Low | Ref | Ref | ||
High | 1.954 (1.101–3.466) | 0.022 | 1.332 (0.730–2.431)a | 0.350a | |
miR-144-3p level | Low | Ref | Ref | ||
High | 0.427 (0.238–0.765) | 0.004 | 0.365 (0.196–0.681)b | 0.002b | |
Age | < 65 | Ref | |||
≥ 65 | 0.649 (0.280–1.503) | 0.307 | |||
Gender | Male | Ref | |||
Female | 0.913 (0.375–2.224) | 0.842 | |||
Smoke | No | Ref | |||
Yes | 0.909 (0.384–2.153) | 0.828 | |||
Clinical Stage | IA | Ref | 0.039 | Ref | 0.221 |
IB | 2.830 (0.255–31.346) | 0.397 | 3.088 (0.275–34.686) | 0.361 | |
IIA | 5.361 (0.626–45.921) | 0.125 | 4.805 (0.550–41.949) | 0.156 | |
IIB | 9.739 (1.186–79.956) | 0.034 | 8.430 (0.995–71.386) | 0.050 | |
IIIA | 17.498 (2.100–145.829) | 0.008 | 13.287 (1.442–122.460) | 0.022 | |
IIIB | 19.248 (1.157–320.344) | 0.039 | 14.606 (0.812–262.349) | 0.069 | |
IL-1β level | Low | Ref | Ref | ||
High | 3.106 (1.218–7.917) | 0.018 | 1.531 (0.503–4.657) | 0.453 | |
TNF-α level | Low | Ref | |||
High | 0.810 (0.357–1.839) | 0.615 | |||
miR-144-3p level | Low | Ref | |||
High | 1.216 (0.533–2.777) | 0.642 |
aMultivatiate model including Age, Clinical Stage, Target therapy, IL-1β & TNF-α.
bMultivatiate model including Age, Clinical Stage, Target therapy, miR-144-3p & TNF-α.